Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 2,146 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $67.23, for a total value of $144,275.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Scott Biller also recently made the following trade(s):

  • On Monday, September 11th, Scott Biller sold 15,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.00, for a total value of $975,000.00.
  • On Friday, September 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $61.99, for a total value of $133,030.54.
  • On Wednesday, August 2nd, Scott Biller sold 23,146 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $59.60, for a total value of $1,379,501.60.
  • On Friday, July 7th, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $55.00, for a total value of $118,030.00.

Shares of Agios Pharmaceuticals, Inc. (AGIO) traded up 1.39% on Wednesday, hitting $70.25. The stock had a trading volume of 1,017,271 shares. The firm has a 50 day moving average of $62.68 and a 200 day moving average of $55.80. The stock’s market cap is $3.40 billion. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $71.40.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. During the same quarter last year, the firm earned ($1.47) earnings per share. The firm’s quarterly revenue was up 62.1% compared to the same quarter last year. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) Insider Sells 2,146 Shares of Stock” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/insider-selling-agios-pharmaceuticals-inc-agio-insider-sells-2146-shares-of-stock/1608600.html.

Institutional investors have recently bought and sold shares of the stock. Swiss National Bank boosted its stake in shares of Agios Pharmaceuticals by 3.4% in the first quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock valued at $3,233,000 after buying an additional 1,800 shares in the last quarter. Spark Investment Management LLC boosted its stake in shares of Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after buying an additional 49,400 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock valued at $15,410,000 after buying an additional 20,336 shares in the last quarter. Hood River Capital Management LLC boosted its stake in shares of Agios Pharmaceuticals by 2.3% in the second quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock valued at $6,115,000 after buying an additional 2,626 shares in the last quarter. Finally, TD Asset Management Inc. boosted its stake in shares of Agios Pharmaceuticals by 4.9% in the second quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $1,544,000 after buying an additional 1,400 shares in the last quarter. Hedge funds and other institutional investors own 94.40% of the company’s stock.

Several equities research analysts have commented on the company. BidaskClub lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 price objective (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Needham & Company LLC upped their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $83.00 price objective (up previously from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. Finally, Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $75.20.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.